top of page

We deliver streamlined solutions to enable patients faster access to innovative medicines

LITERATURE REVIEW
&
EVIDENCE SYNTHESIS

With our unique approach to conducting systematic literature reviews and indirect treatment comparisons, we can  deliver submission-ready results in >80% less time*.

*Available in select disease areas, please reach out for further information

HEALTH ECONOMIC MODELLING

With our unique approach, we can rapidly build, develop, and localise high quality and rigorous economic models for pricing, decision-making, and submission purposes. 

STATISTICAL DATA ANALYSIS

With our deep technical expertise and knowledge, we can perform statistical analyses for HTA submissions, economic modelling, and publications.

HEALTH TECHNOLOGY ASSESSMENT

With our extensive experience with HTA submissions globally, we can develop HTA strategies, understanding

 evidence requirements, and develop submissions in all stages of drug development.

Literature Review
&
Evidence Synthesis

Our unique approach to conducting systematic literature reviews and indirect treatment comparisons helps us deliver submission-ready results in >80% less time*.

Systematic Literature Review

Evidence Synthesis

Localisation

Our team can generate robust, high quality literature reviews including:

​

​

  • Systematic literature reviews for submissions and evidence synthesis

  • Targeted literature reviews

  • Rapid literature reviews

Our team have extensive knowledge and experience with evidence synthesis methods including:​

​

  • Indirect treatment comparisons

  • Network meta-analysis

  • Matching-adjusted indirect comparisons

  • Multi-level network meta-regression

Our team have supported many countries globally with localisations and adaptations of HTA deliverables:​

​

  • Adaptation of deliverable reports to suit local requirements

  • Localisation of SLR and evidence synthesis deliverables according to local methodological guidelines

Our standardised tools* and solutions enable us to rapidly build and develop high quality and rigorous economic models for pricing, decision-making, and submission purposes.

Cost-Effectiveness Models

Health Economic Tools

Localisation

  • Early models

  • Disease agnostic models

  • Global economic models

  • Technical and strategic model QC and validation

  • Advisory & strategic support with economic modelling

  • Budget impact models

  • Cost per response models

  • Cost consequence models

  • Price-volume trade-off models

  • Bespoke models

  • Adaptation of deliverable reports to suit local requirements

  • Modification of health economic tools according to local methodological guidelines

The Evimed team has considerable knowledge and experience in developing, reviewing, and localising health economic models, and have worked across multiple therapeutic areas including oncology, immunology, neurosciences, respiratory, vaccines, and eyecare.

White Structure

Health Economic Modelling

Statistical Data Analysis

With our deep technical expertise and knowledge, we can perform statistical analyses for HTA submissions, economic modelling, and publications.

Health Economics & Outcomes

Post-hoc Analysis of Clinical Trials

Our team have extensive experience in conducting statistical analyses to generate inputs for health economic assessments, outcomes research, and bespoke analyses to support reimbursement dossiers and secondary publications.​

  • Quality of life analyses

  • Health-state utility values

  • Survival analysis

  • Treatment switching

  • Adverse events

  • Cost inputs

  • Disutility

  • Post-hoc analysis of clinicals to support reimbursement dossiers in line with local guidelines 

  • Analyses using tailored methodological approaches to support publications

We have extensive experience developing HTA strategies, understanding evidence requirements, and preparing for submissions in all stages of drug development.

HTA & Submission Strategy

Trial Design and Evidence Planning

Early Evaluation and Decision-Making

​

  • Advice on overall HTA & reimbursement submissions strategy

  • Expected HTA & reimbursement outcomes based on planned programme and efficacy/safety profile

  • Identification of risks and mitigation strategies

​

  • Assessment of proposed development programme against competitors & agency expectations

  • Identification of risks, mitigation strategies, and potential changes to development programme to support desired outcomes

​​

  • Assessment of reimbursement potential of early pipeline assets

  • Trade-off assessments for milestone or launch decision

  • Evaluation of business development opportunities

The Evimed team has extensive experience in HTA, collectively contributing to over 100 submissions across multiple geographies. The team has also supported the design of pivotal programs to maximize acceptability for HTA, development of HTA & submission strategies, and the early evaluation of development programs.

Health Technology Assessment

bottom of page